Alpha-Mannosidosis
Conditions
Brief summary
The main objectives of the study are to evaluate safety and efficacy of repeated treatment with recombinant human alfa-mannosidase of patients with alfa-mannosidosis aged less than 6 years
Detailed description
The Primary endpoints of the study include: * Safety and tolerability of velmanase alfa as per Adverse events (AEs, including IRR), vital signs, laboratory parameters (hematology, biochemistry and urinanalysis) * Detection of anti-velmanase alfa antibodies and neutralizing/inhibitory antibodies The Secondary endpoints include changes from baseline to 24 months for the following parameters. Efficacy outcomes: * Serum oligosaccharides * Functional capacity: Peabody Developmental Motor Scale - 2nd edition (PDMS-2) scores, Mullen's Scale of Early Learning (MSEL) scores, Bruininks-Oseretsky Test Of Motor Proficiency-2nd Edition (BOT-2), when applicable by age (from 4 years) or upon the judgment of the physician * Endurance: 3-Minute Stair Climb Test (3MSCT) and 6-Minute Walk Test (6MWT) in pediatric patients from 4 years of age, or when applicable according to the judgment of the physician, 2-Minute Walk Test (2MWT) in pediatric patients below 4 years of age, or when applicable according to the judgment of the physician * Hearing evaluation: Otoacoustic Emissions (OAE) testing, Automatic Auditory Brainstem Response (A-ABR) audiometry * Immunological profile, when applicable upon the judgment of the physician: * CSF biomarkers: Tau protein (Tau), Neurofilament Protein Light (NFL), Glial Fibrillary Acidic Protein (GFAp), Oligosaccharides * Assessment of quality of life via Questionnaire to parents * Assessment of mannose-rich oligosaccharides in brain tissue, MRI * Pharmacokinetic parameters
Interventions
DRUGVelmanase Alfa (e.g. Lamazym)
iv infusion treatment
Sponsors
Cromsource
Chiesi Farmaceutici S.p.A.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
No minimum to 6 Years
Healthy volunteers
No
Inclusion criteria
1. Patient's custodial parent(s) must provide signed ICF prior to the involvement of the patient in any trial-related activities 2. The subject's custodial parent(s) must have the ability to comply with the protocol 3. The subject must have a confirmed diagnosis of alpha-mannosidosis as defined by alpha-mannosidase activity in leukocytes or fibroblasts \< 10% of normal activity (historical data) 4. The subject must have an age at the time of screening \< 6 years.
Exclusion criteria
1. The subject's diagnosis cannot be confirmed by alpha-mannosidase activity \< 10% of normal activity 2. Presence of known chromosomal abnormality and syndromes affecting psychomotor development, other than alpha-mannosidosis 3. History of BMT 4. Presence of known clinically significant cardiovascular, hepatic, pulmonary, or renal disease or other medical conditions that, in the opinion of the Investigator, would preclude participation in the trial 5. Any other medical condition or serious intercurrent illness, or extenuating circumstance that, in the opinion of the Investigator, would preclude participation in the trial 6. Planned major surgery that, in the opinion of the Investigator, would preclude participation in the trial 7. Participation in other interventional trials testing the IMP within the last 3 months.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety and tolerability of velmanase alfa as per Adverse events | From baseline throughout study completion, at least of 2 years | Safety and tolerability assessed as per AEs including infusion-related reactions \[IRRs\] |
| Safety and tolerability of velmanase alfa as per vital signs | From baseline throughout study completion, at least of 2 years | — |
| Safety and tolerability of velmanase alfa as per clinical laboratory parameters as per hematology | From baseline throughout study completion, at least of 2 years | — |
| Safety and tolerability of velmanase alfa as per clinical laboratory parameters as per blood biochemistry | From baseline throughout study completion, at least of 2 years | — |
| Safety and tolerability of velmanase alfa as per clinical laboratory parameters as per urinalysis | From baseline throughout study completion, at least of 2 years | — |
| Detection of anti-velmanase alfa-IgG antibodies (ADA) and neutralizing/inhibitory antibodies | From baseline throughout study completion, at least of 2 years | Serum samples for anti-velmanase alfa-IgG antibody (ADA) testing will be obtained |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Hearing evaluation: Otoacoustic Emissions (OAE) testing | From baseline throughout study completion, at least for 2 years | — |
| Hearing evaluation: Automatic Auditory Brainstem Response (A-ABR) audiometry | From baseline throughout study completion, at least for 2 years | — |
| Immunological profile when applicable upon the judgement of the physician (Serum IgG, IgA, IgM; in vitro synthesis of IgG; in vitro proliferative response and Immunophenotype) | From baseline throughout study completion, at least for 2 years | — |
| CSF biomarkers: Tau protein (Tau) § Neurofilament Protein Light (NFL) § Glial Fibrillary Acidic Protein (GFAp) § Oligosaccharides | From baseline throughout study completion, at least for 2 years | — |
| Assessment of quality of life via Questionnaire | From baseline throughout study completion, at least for 2 years | — |
| Assessment of mannose-rich oligosaccharides in brain tissue, as measured by Magnetic Resonance Spectroscopy (MRS) | From baseline throughout study completion, at least for 2 years | — |
| Magnetic Resonance Imaging (MRI) in white matter, gray matter and in centrum semi ovale, and diffusion-MRI of the brain, | From baseline throughout study completion, at least for 2 years | — |
| Pharmacokinetic parameters to determine Cmax (Peak Concentration) | At first dose (visit 1) and after 6 months (visit 26) | — |
| Evaluation of levels of Serum oligosaccharides | From baseline throughout study completion, at least for 2 years | Assessment of change from baseline in levels of Serum oligosaccharides |
| Pharmacokinetic parameters to determine Area Under Curve (AUC24) | At first dose (visit 1) and after 6 months (visit 26) | — |
| Pharmacokinetic parameters to determine AUClast (Area Under Curve After The Last Count) | At first dose (visit 1) and after 6 months (visit 26) | — |
| Pharmacokinetic parameters to determine AUCinf (Area Under Curve From Time Zero To Infinity) | At first dose (visit 1) and after 6 months (visit 26) | — |
| Pharmacokinetic parameters to determine tmax (Time To Peak Concentration) | At first dose (visit 1) and after 6 months (visit 26) | — |
| Pharmacokinetic parameters to determine CL (Clearance) | At first dose (visit 1) and after 6 months (visit 26) | — |
| Pharmacokinetic parameters to determine t1/2 (Elimination Half-Life) | At first dose (visit 1) and after 6 months (visit 26) | — |
| Pharmacokinetic parameters to determine Rac (Obs) Observed Accumulation Ratio | At first dose (visit 1) and after 6 months (visit 26) | — |
| Pharmacokinetic parameters to determine Ctrough (Trough Plasma Concentration) | At first dose (visit 1) and after 6 months (visit 26) | — |
| Functional capacity: The Peabody Developmental Motor Scale test (PDMS-2) | From baseline throughout study completion, at least for 2 years | Serum samples for anti-velmanase alfa-IgG antibody (ADA) testing will be obtained |
| Functional capacity: Bruininks-Oseretsky test of Motor Proficiency (BOT-2) when applicable by age (from 4 years) or upon the judgment of the physician | From baseline throughout study completion, at least for 2 years | — |
| Functional capacity: Mullen Scales of Early Learning (MSEL) | From baseline throughout study completion, at least for 2 years | — |
| Endurance: 3-Minute Stair Climb Test (3MSCT) in pediatric patients from 4 years of age, or when applicable according to the judgment of the physician | From baseline throughout study completion, at least for 2 years | — |
| Endurance: 6-Minute Walk Test (6MWT) in pediatric patients from 4 years of age, or when applicable according to the judgment of the physician 2-Minute Walk Test (2MWT) in pediatric patients below 4 years of age | From baseline throughout study completion, at least for 2 years | — |
Countries
Austria, Denmark, France, Germany, Italy
Outcome results
None listed